1. Home
  2. WINT vs UK Comparison

WINT vs UK Comparison

Compare WINT & UK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WINT
  • UK
  • Stock Information
  • Founded
  • WINT 1992
  • UK 2015
  • Country
  • WINT United States
  • UK China
  • Employees
  • WINT N/A
  • UK N/A
  • Industry
  • WINT Biotechnology: Biological Products (No Diagnostic Substances)
  • UK Business Services
  • Sector
  • WINT Health Care
  • UK Consumer Discretionary
  • Exchange
  • WINT Nasdaq
  • UK Nasdaq
  • Market Cap
  • WINT 2.0M
  • UK 1.7M
  • IPO Year
  • WINT 1995
  • UK N/A
  • Fundamental
  • Price
  • WINT $0.12
  • UK $1.16
  • Analyst Decision
  • WINT Hold
  • UK
  • Analyst Count
  • WINT 1
  • UK 0
  • Target Price
  • WINT $7.00
  • UK N/A
  • AVG Volume (30 Days)
  • WINT 7.3M
  • UK 107.2K
  • Earning Date
  • WINT 11-27-2024
  • UK 03-15-2025
  • Dividend Yield
  • WINT N/A
  • UK N/A
  • EPS Growth
  • WINT N/A
  • UK N/A
  • EPS
  • WINT N/A
  • UK N/A
  • Revenue
  • WINT N/A
  • UK $42,470,655.00
  • Revenue This Year
  • WINT N/A
  • UK N/A
  • Revenue Next Year
  • WINT N/A
  • UK N/A
  • P/E Ratio
  • WINT N/A
  • UK N/A
  • Revenue Growth
  • WINT N/A
  • UK N/A
  • 52 Week Low
  • WINT $0.11
  • UK $1.04
  • 52 Week High
  • WINT $14.75
  • UK $3.70
  • Technical
  • Relative Strength Index (RSI)
  • WINT 15.60
  • UK 46.54
  • Support Level
  • WINT $0.21
  • UK $1.13
  • Resistance Level
  • WINT $0.33
  • UK $1.35
  • Average True Range (ATR)
  • WINT 0.03
  • UK 0.10
  • MACD
  • WINT 0.00
  • UK -0.00
  • Stochastic Oscillator
  • WINT 2.15
  • UK 32.37

About WINT Windtree Therapeutics Inc.

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

About UK Ucommune International Ltd

Ucommune International Ltd is a flexible office space provider and manager based in the People's Republic of China (PRC). The company offers long-term leasing, on-demand, and short-term leasing solutions to freelancers, start-up entrepreneurs, small and medium enterprises, and corporations. They provide fully-serviced and well-furnished office spaces on a flexible basis. The members of the Ucommune community, which includes individuals and enterprises registered on the U bazaar mobile app, can avail of these services. The company has three operating segments: Workspace membership, Marketing and branding services, and Other services. Marketing and branding services generate the majority of the company's revenue.

Share on Social Networks: